Zynerba Reports Results of Zygel in P-II (INSPIRE) Trial for the Treatment of Patients with 22q11.2 Deletion Syndrome
Shots:
- The P-II (INSPIRE) trial evaluates Zygel (250/500mg, qd) in 30 children & adolescents aged 4 through 15yrs. with 22q11.2 deletion syndrome at 2 clinical sites in Australia and 1 in the US
- The results showed an improvement from baseline in multiple efficacy assessments @14wks. including ADAMS, ABC-C, PARS – R & CGI-I, 75% were rated as “improved”, “much improved” or “very much improved” with 62.5% being “much improved” or “very much improved”, was well tolerated, and the safety profile was consistent with prior data from other Zygel clinical trials
- 1 patient discontinued treatment due to AEs not related to Zygel. The company has chosen to focus its resources on 22q & FXS, both of which have been received ODD from the US FDA
Ref: GlobalNewswire | Image: Zynerba
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
